<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="msc70084" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Musculoskeletal Care</journal-id><journal-id journal-id-type="iso-abbrev">Musculoskeletal Care</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">MSC</journal-id><journal-title-group><journal-title>Musculoskeletal Care</journal-title></journal-title-group><issn pub-type="ppub">1478-2189</issn><issn pub-type="epub">1557-0681</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11949773</article-id><article-id pub-id-type="pmcid-ver">PMC11949773.1</article-id><article-id pub-id-type="pmcaid">11949773</article-id><article-id pub-id-type="pmcaiid">11949773</article-id><article-id pub-id-type="pmid">40148116</article-id><article-id pub-id-type="doi">10.1002/msc.70084</article-id><article-id pub-id-type="publisher-id">MSC70084</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Trends in Drug Claims for Non&#8208;Specific Low Back Pain in Qu&#233;bec, 1997 to 2018</article-title></title-group><contrib-group><contrib id="msc70084-cr-0001" contrib-type="author"><name name-style="western"><surname>Ly</surname><given-names initials="A">Antarou</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7111-4054</contrib-id><xref rid="msc70084-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="msc70084-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="msc70084-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="msc70084-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="msc70084-cr-0002" contrib-type="author"><name name-style="western"><surname>Sirois</surname><given-names initials="C">Caroline</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3294-7883</contrib-id><xref rid="msc70084-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="msc70084-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="msc70084-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="msc70084-cr-0003" contrib-type="author" corresp="yes"><name name-style="western"><surname>Dionne</surname><given-names initials="CE">Clermont E.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0806-5573</contrib-id><xref rid="msc70084-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="msc70084-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="msc70084-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><address><email>clermont.dionne@crchudequebec.ulaval.ca</email></address></contrib></contrib-group><aff id="msc70084-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Social and Preventive Medicine</named-content>
<institution>Universit&#233; Laval</institution>
<city>Qu&#233;bec City</city>
<country country="CA">Canada</country>
</aff><aff content-type="private-address" id="msc70084-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>Centre de Recherche du CHU de Qu&#233;bec&#8208;Universit&#233; Laval</institution>
<city>Qu&#233;bec City</city>
<country country="CA">Canada</country>
</aff><aff content-type="private-address" id="msc70084-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Centre d'Excellence sur le Vieillissement de Qu&#233;bec (CEVQ) of the CIUSSS de la Capitale&#8208;Nationale</institution>
<city>Qu&#233;bec City</city>
<country country="CA">Canada</country>
</aff><aff content-type="private-address" id="msc70084-aff-0004">
<label>
<sup>4</sup>
</label>
<institution>Centre National de la Recherche Scientifique et Technologique (CNRST)/Institut de Recherche en Sciences de la Sant&#233; (IRSS)</institution>
<city>Ouagadougou</city>
<country country="BF">Burkina Faso</country>
</aff><aff id="msc70084-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Faculty of Pharmacy</named-content>
<institution>Universit&#233; Laval</institution>
<city>Qu&#233;bec City</city>
<country country="CA">Canada</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold> Clermont E. Dionne<break/>
(<email>clermont.dionne@crchudequebec.ulaval.ca</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2025</year></pub-date><volume>23</volume><issue seq="20">2</issue><issue-id pub-id-type="pmc-issue-id">485449</issue-id><issue-id pub-id-type="doi">10.1002/msc.v23.2</issue-id><elocation-id>e70084</elocation-id><history><date date-type="rev-recd"><day>01</day><month>3</month><year>2025</year></date><date date-type="received"><day>28</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>11</day><month>3</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>28</day><month>03</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>29</day><month>03</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-29 00:25:14.097"><day>29</day><month>03</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Musculoskeletal Care</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="MSC-23-e70084.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:MSC-23-e70084.pdf"/><abstract><title>ABSTRACT</title><sec id="msc70084-sec-0001"><title>Objective</title><p>The aim of this study was to describe temporal trend of drugs claims after an episode of non&#8208;specific low back pain in Qu&#233;bec between 1997 and 2018, by pharmacological class.</p></sec><sec id="msc70084-sec-0002"><title>Methods</title><p>Data came from the <italic toggle="yes">PROspective Qu&#233;bec study on work and health</italic> (PROQ), the R&#233;gie de l'assurance maladie du Qu&#233;bec (RAMQ) and Qu&#233;bec hospital services (Med&#8208;Echo). RAMQ common denomination codes were used to identify the types of medication claimed for an episode of non&#8208;specific low back pain. Multivariate log&#8208;binomial regression models were used to evaluate temporal trends in claims for the main pharmacological classes, taking into account dependence between multiple episodes.</p></sec><sec id="msc70084-sec-0003"><title>Results</title><p>A total of 5214 episodes of non&#8208;specific low back pain were identified in 1658 people between 1997 and 2018. The mean age at the first medical service for low back pain was 64.1&#160;years (standard deviation: 8.3&#160;years). Results show a significant increase in opioid claims between 1997 and 1998 (4.1%) and 2009&#8211;2010 (12.7%) (<italic toggle="yes">p</italic> for trend&#160;=&#160;0.0008), anticonvulsants between 1997 and 1998 (0.0%) and 2011&#8211;2012 (10.5%) (<italic toggle="yes">p</italic> for trend&#160;=&#160;0.0002), and myorelaxants between 1997 and 1998 (2.0%) and 2009&#8211;2010 (8.8%) (<italic toggle="yes">p</italic> for trend&#160;&lt;&#160;0.0001), but no significant change in claims for antidepressants between 1997 and 1998 (0.5%) and 2016&#8211;2017 (2.6%) (<italic toggle="yes">p</italic> for trend&#160;=&#160;0.5508).</p></sec><sec id="msc70084-sec-0004"><title>Conclusion</title><p>Claims for opioids, anticonvulsants and myorelaxants for non&#8208;specific low back pain showed significant upward changes between 1997 and 2018 in Qu&#233;bec, in contrast to antidepressants. These temporal variations in claims were different for each group of drugs, with a greater variation for anticonvulsants.</p></sec></abstract><kwd-group><kwd id="msc70084-kwd-0001">claims</kwd><kwd id="msc70084-kwd-0002">pharmacological classes</kwd><kwd id="msc70084-kwd-0003">Qu&#233;bec</kwd><kwd id="msc70084-kwd-0004">trends</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>Canadian Institutes of Health Research</funding-source></award-group></funding-group><counts><fig-count count="3"/><table-count count="2"/><page-count count="10"/><word-count count="6399"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>June 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:27.03.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group><fn id="msc70084-note-0001"><p>
<bold>Funding:</bold> Data collection for this study was funded by the Canadian Institutes of Health Research (CIHR).</p></fn></fn-group></notes></front><body id="msc70084-body-0001"><sec id="msc70084-sec-0010"><label>1</label><title>Introduction</title><p>Relieving a patient's back pain remains a major challenge for the clinician, particularly in a context marked by the irrational use of painkillers (Chou and Huffman&#160;<xref rid="msc70084-bib-0005" ref-type="bibr">2007</xref>; Fields&#160;<xref rid="msc70084-bib-0012" ref-type="bibr">2011</xref>). The World Health Organisation (WHO) recommends gradual prescription of pain medication, starting with non&#8208;steroidal anti&#8208;inflammatory drugs (NSAIDs) and weak opioids (Vargas&#8208;Schaffer&#160;<xref rid="msc70084-bib-0051" ref-type="bibr">2010</xref>). However, for more than a decade, an 'opioid crisis' has been unfolding in several parts of the world due to the excessive use of these drugs, often resulting in overdose deaths (Hancocks&#160;<xref rid="msc70084-bib-0017" ref-type="bibr">2019</xref>; Hornberger and Chhatwal&#160;<xref rid="msc70084-bib-0018" ref-type="bibr">2021</xref>; Krausz et&#160;al.&#160;<xref rid="msc70084-bib-0028" ref-type="bibr">2021</xref>). Some of these opioid users are victims of misguided prescribing by healthcare professionals (Khan et&#160;al.&#160;<xref rid="msc70084-bib-0026" ref-type="bibr">2019</xref>; Lev et&#160;al.&#160;<xref rid="msc70084-bib-0032" ref-type="bibr">2016</xref>; Manchikanti and Kaye&#160;<xref rid="msc70084-bib-0034" ref-type="bibr">2016</xref>; Skolnick&#160;<xref rid="msc70084-bib-0044" ref-type="bibr">2018</xref>). In addition to opioids, antidepressants and anticonvulsants prescribed for pain also contribute to overdose deaths (Chaves et&#160;al.&#160;<xref rid="msc70084-bib-0003" ref-type="bibr">2022</xref>; Darke et&#160;al.&#160;<xref rid="msc70084-bib-0008" ref-type="bibr">2022</xref>; Soni and Walters&#160;<xref rid="msc70084-bib-0045" ref-type="bibr">2019</xref>; Tharp et&#160;al.&#160;<xref rid="msc70084-bib-0048" ref-type="bibr">2019</xref>).</p><p>In recent years, there has been an upward trend in the prescription of opioids in several countries around the world. In the United States, the use of prescription opioids increased by 7.2% between 1999 and 2016 (Stokes et&#160;al.&#160;<xref rid="msc70084-bib-0047" ref-type="bibr">2019</xref>). However, recent estimates in the United States (2015&#8211;2020) show an overall downward trend in opioid prescribing (IQVIA&#160;<xref rid="msc70084-bib-0020" ref-type="bibr">2020</xref>). In line with this trend, opioid use in Australia increased by 0.6% between 2013 and 2018, and decreased by 0.3% after 2018 (Lalic et&#160;al.&#160;<xref rid="msc70084-bib-0031" ref-type="bibr">2019</xref>). In Canada, there has been an overall decrease in the prevalence of opioid prescribing from 13.1% in 2015 to 11.5% in 2020 (Pierre and Daniel&#160;<xref rid="msc70084-bib-0038" ref-type="bibr">2023</xref>). Furthermore, the effects of opioids were more noticeable in Canada's English&#8208;speaking provinces and territories, which had the highest prescription prevalence in the country (up to 16.3% of opioids dispensed in pharmacies in the city of Edmonton in 2015) (Pierre and Daniel&#160;<xref rid="msc70084-bib-0038" ref-type="bibr">2023</xref>). In the province of Qu&#233;bec, Health Canada statistics show that the prevalence of opioid prescribing fell from 11.6% in 2015 to 10.0% in 2020 (Pierre and Daniel&#160;<xref rid="msc70084-bib-0038" ref-type="bibr">2023</xref>). Guidelines have been established to provide a better framework for prescribing different classes of pain medication (Bussi&#232;res et&#160;al.&#160;<xref rid="msc70084-bib-0002" ref-type="bibr">2008</xref>; CIHI&#160;<xref rid="msc70084-bib-0007" ref-type="bibr">2023</xref>). In the specific case of low back pain, a treatment guide has been developed to assist clinicians (Kreiner et&#160;al.&#160;<xref rid="msc70084-bib-0029" ref-type="bibr">2020</xref>; Qaseem et&#160;al.&#160;<xref rid="msc70084-bib-0040" ref-type="bibr">2017</xref>).</p><p>In the Canadian context, and more specifically in Qu&#233;bec, there is very limited information on the use of pain medication in adults with low back pain, particularly with regards to opioids. Although prescribing trends have been described globally (Encinosa et&#160;al.&#160;<xref rid="msc70084-bib-0011" ref-type="bibr">2022</xref>; Gorfinkel et&#160;al.&#160;<xref rid="msc70084-bib-0016" ref-type="bibr">2022</xref>; Hwang et&#160;al.&#160;<xref rid="msc70084-bib-0019" ref-type="bibr">2016</xref>; Kantor et&#160;al.&#160;<xref rid="msc70084-bib-0025" ref-type="bibr">2015</xref>; Meng et&#160;al.&#160;<xref rid="msc70084-bib-0035" ref-type="bibr">2013</xref>; Noordam et&#160;al.&#160;<xref rid="msc70084-bib-0037" ref-type="bibr">2015</xref>; Piper et&#160;al.&#160;<xref rid="msc70084-bib-0039" ref-type="bibr">2018</xref>; West et&#160;al.&#160;<xref rid="msc70084-bib-0053" ref-type="bibr">2015</xref>), it is less clear how the use of opioids, antidepressants, anticonvulsants and myorelaxants has evolved in people with non&#8208;specific low back pain. Tracking these trends would provide a better understanding of changes in prescribing practices over time. In addition, the introduction of new molecules such as duloxetine (Knadler et&#160;al.&#160;<xref rid="msc70084-bib-0027" ref-type="bibr">2011</xref>), gabapentin and pregabalin (Robertson et&#160;al.&#160;<xref rid="msc70084-bib-0042" ref-type="bibr">2019</xref>) to treat patients with non&#8208;specific low back pain, as well as advances in knowledge, have most likely led to changes in prescribing behaviour. It is therefore necessary to examine changes over time not only in the prevalence of opioid claims, but also in that of other pharmacological classes used for the treatment of pain.</p><p>The aim of this study was to describe changes in the prevalence of claims for drugs prescribed for non&#8208;specific low back pain in white&#8208;collar workers of Qu&#233;bec between 1997 and 2018 by main pharmacological class: opioids, antidepressants, anticonvulsants, and myorelaxant drugs.</p></sec><sec id="msc70084-sec-0020"><label>2</label><title>Methods</title><sec id="msc70084-sec-0030"><label>2.1</label><title>Background, Study Design and Data Sources</title><p>To carry out this study, we took advantage of the opportunity offered by the occupational health research programme of the Centre Hospitalier Universitaire (CHU) de Qu&#233;bec&#8208;Universit&#233; Laval. This programme has been instituted and follows a cohort of white&#8208;collar workers called <italic toggle="yes">PROQ (PROspective Qu&#233;bec study on work and health</italic>). This is a 24&#8208;year prospective cohort of 9188 white&#8208;collar workers from 19 public and semi&#8208;public organisations in the Qu&#233;bec City region (Trudel et&#160;al.&#160;<xref rid="msc70084-bib-0049" ref-type="bibr">2018</xref>). The cohort was initiated in 1991&#8211;1993 with two follow&#8208;up periods, 8&#160;years (1999&#8211;2001) and 24&#160;years (2015&#8211;2018) later. The flowchart of the cohort is presented in Appendix 1 in Supporting Information&#160;<xref rid="msc70084-sup-0001" ref-type="supplementary-material">S1</xref>. The sample comprised a wide range of white&#8208;collar jobs, including senior managers (10.4%), professionals (34.1%), technicians (19.7%), clerical workers (32.7%) and other types of jobs (3.2%).</p><p>In addition to the data collected from the workers themselves, this study included their medico&#8208;administrative data. These medico&#8208;administrative data consisted of data from the R&#233;gie de l'assurance maladie du Qu&#233;bec (RAMQ), the <italic toggle="yes">Maintenance et exploitation des donn&#233;es pour l'&#233;tude de la client&#232;le hospitali&#232;re</italic> (Med&#8208;&#201;cho), and data from private insurers in the province of Qu&#233;bec (Desjardins, La Capitale and SSQ). In the current study, we did not use data from private insurers because the pharmaceutical data from this source were not complete. RAMQ data consisted of medical services data and pharmaceutical data, and Med&#8208;&#201;cho data consisted of hospital stay data.</p></sec><sec id="msc70084-sec-0040"><label>2.2</label><title>Data Processing and Selection of Participants</title><p>Figure&#160;<xref rid="msc70084-fig-0001" ref-type="fig">1</xref> summarises the criteria used to select participants for the study. This selection included several steps:</p><fig position="float" fig-type="FIGURE" id="msc70084-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Participant selection criteria. MA: medico&#8208;administrative; RAMQ: R&#233;gie d'assurance maladie du Qu&#233;bec (Quebec health insurance board).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="MSC-23-e70084-g003.jpg"/></fig><p>
<italic toggle="yes">1st step:</italic> Merging the cohort data with the above&#8208;mentioned medico&#8208;administrative data. As the RAMQ pharmaceutical data were available from 1997, we ensured that the medical data were aligned from the same date in order to have complete follow&#8208;up of the participants. We excluded all participants who did not have medico&#8208;administrative data.</p><p>
<italic toggle="yes">2nd step:</italic> Excluding participants who did not have a period of eligibility for RAMQ drug insurance between 1997 and 2018. This action made it possible to retain the participants in the cohort who had at least one period of eligibility for RAMQ drug insurance. This period of eligibility corresponded to the period during which the individual was covered by RAMQ for reimbursement of drugs claimed in pharmacies. Individuals eligible for the RAMQ drug insurance plan include people who are not eligible for a private plan or who have only complementary private coverage, people aged 65 or over, recipients of last&#8208;resort financial assistance and other holders of a claims booklet, as well as the children of people insured by the public plan (RAMQ&#160;<xref rid="msc70084-bib-0041" ref-type="bibr">2011</xref>).</p><p>
<italic toggle="yes">3rd step:</italic> Given that the study focused on drug claims among people suffering from non&#8208;specific low back pain, retaining only cases of low back pain, excluding all other diagnostic codes. To identify cases of low back pain, we applied an identification algorithm that included anyone who had at least one diagnostic code for low back pain in medical or hospital service data between 1997 and 2018 (Ly et&#160;al.&#160;<xref rid="msc70084-bib-0033" ref-type="bibr">2023</xref>). Cases of low back pain were identified using the International Classification of Diseases (ICD&#8208;9 and ICD&#8208;10) codes in the Qu&#233;bec and Canadian versions. The list of codes can be found in Appendix 2 in Supporting Information&#160;<xref rid="msc70084-sup-0001" ref-type="supplementary-material">S1</xref>.</p><p>
<italic toggle="yes">4th step:</italic> The final step in this selection process was checking whether the low back pain occurred during a period of eligibility for RAMQ drug insurance, which made it possible to finally retain participants for whom data on drug claims were available during an episode of non&#8208;specific low back pain.</p></sec><sec id="msc70084-sec-0050"><label>2.3</label><title>Creation of Episodes of Non&#8208;Specific Low Back Pain</title><p>The initial idea was to measure the prevalence of drugs requested during the 7&#160;days following a medical visit for low back pain. A descriptive analysis showed that the data included visits for low back pain where the interval between two visits was less than 1&#160;week. Applying the initial strategy could have led to an overlap in the measurement window when the medical visits were fairly close, with the result that the same drug could have been counted twice in the prevalence estimate for two separate medical visits. We thus grouped cases of low back pain with a difference of&#160;&#8804;&#160;7&#160;days to create 'episodes' of low back pain. An 'episode' could therefore consist of one or more diagnoses of non&#8208;specific low back pain.</p></sec><sec id="msc70084-sec-0060"><label>2.4</label><title>Identifying Pharmacological Classes and Measuring Prevalence</title><p>To measure prevalence, we looked at drug claims made during and within 7&#160;days of an episode of low back pain. The drugs studied were grouped into four pharmacological classes: opioids, antidepressants, anticonvulsants, and myorelaxants. For each drug class, we identified all the drugs, alone or in combination, that can be used to relieve low back pain. We first compiled a list of these drugs based on the literature and expert opinion (Kantor et&#160;al.&#160;<xref rid="msc70084-bib-0025" ref-type="bibr">2015</xref>; Soprano et&#160;al.&#160;<xref rid="msc70084-bib-0046" ref-type="bibr">2020</xref>; Stokes et&#160;al.&#160;<xref rid="msc70084-bib-0047" ref-type="bibr">2019</xref>). We selected drugs that were claimed at least once during the study period, including oral and injectable forms, suppositories, and skin patches. Medications claimed during an episode of low back pain were identified using the common name code (Appendix 3 in Supporting Information&#160;<xref rid="msc70084-sup-0001" ref-type="supplementary-material">S1</xref>). This code is assigned by the RAMQ and refers to the unique scientific name of the drug's active ingredient. We excluded certain opioids prescribed for the treatment of opioid dependence, such as naltrexone. Each drug group was treated dichotomously (e.g., opioids claimed: yes vs. no). The prevalence of claims for drugs in each pharmacological class was measured as the proportion of individuals who claimed at least one drug in that class within 7&#160;days of an episode of low back pain during a 2&#8208;year period. The measure was repeated for the entire follow&#8208;up period, i.e., for 11 observation points.</p></sec><sec id="msc70084-sec-0070"><label>2.5</label><title>Indication and Consideration of Co&#8208;morbidities</title><p>Given that the indication of the drugs dispensed following a medical consultation was not available, we inferred that the drugs were related to the medical visit based on the dispensing date. To be associated with an episode of low back pain, the dispensing date had to fall between the start date of the episode and up to 7&#160;days after its end. We also added other criteria to reinforce this inference by considering certain comorbidities for which these drugs could be prescribed. Several algorithms were therefore constructed and applied for this purpose:<list list-type="order"><list-item><p>If the person had been hospitalised for cancer 1&#160;year before the onset of the episode of low back pain or if the person had consulted or had been hospitalised for other musculoskeletal disorders related to the neck, shoulder, fibromyalgia, osteoarthritis or arthritis 6&#160;months before the onset of the episode of low back pain, we excluded opioid claims in the estimate of opioid prevalence.</p></list-item><list-item><p>If the person had consulted or had been hospitalised for depression or other mental disorders (anxiety disorders, bipolar disorders, and other phobic disorders) 1&#160;year before the onset of the episode of low back pain, we excluded claims for antidepressants in the estimate of the prevalence of antidepressants.</p></list-item><list-item><p>If the person had consulted or had been hospitalised for a diagnosis of epilepsy or bipolar disorder 1&#160;year before the onset of the episode of low back pain, we excluded anticonvulsant claims in the estimate of the prevalence of anticonvulsants.</p></list-item><list-item><p>Finally, if the person had consulted or had been hospitalised for other musculoskeletal disorders related to the neck, shoulder, fibromyalgia, osteoarthritis, and arthritis 6&#160;months before the onset of the episode of low back pain, we also excluded claims for myorelaxants in estimating the prevalence of myorelaxants.</p></list-item></list>
</p><p>It was also possible to identify the various pathologies mentioned above using the ICD&#8208;9 and ICD&#8208;10 codes of the Qu&#233;bec and Canadian versions (Appendix 4 in Supporting Information&#160;<xref rid="msc70084-sup-0001" ref-type="supplementary-material">S1</xref>).</p></sec><sec id="msc70084-sec-0080"><label>2.6</label><title>Statistical Methods</title><p>A descriptive analysis was performed on our sample. Patient age was measured at the time of low back pain diagnosis. Means and standard deviations (SD) were used to describe continuous variables, while frequencies were used for categorical variables. Time trends in claim prevalence during an episode of low back pain and over a 7&#8208;day window following this episode were examined for the different drug groups. The period, composed of the grouping of 2 calendar years to obtain more case of low back pain, was used as the continuous independent variable. Log&#8208;binomial regression was used to perform linear trend tests and the null hypothesis that the slope is equal to 0 was tested. In order to take account of the dependence between observations due to the multiple episodes of low back pain possible for the same individual, a robust variance was calculated using generalised estimating equations (GEE). The proportions per period calculated for visualisation purposes were used to identify, where appropriate, a cut&#8208;off period of different fluctuations within the full study period and the linear trend was tested separately for each cut&#8208;off period. To quantify the changes, we reported prevalence ratios (PRs) for the cut&#8208;off periods of different fluctuations within the full study period. These prevalence ratios correspond to an estimate of the change in the prevalences when comparing time t and time (t&#8208;1) over the selected period. All models were adjusted for age at diagnosis of low back pain. Sensitivity analyses were performed by examining temporal trends over windows of 14 and 28&#160;days following the episode of low back pain. All analyses were performed using SAS version 9.4 statistical software (SAS Institute Inc., Cary, North Carolina, USA).</p></sec></sec><sec id="msc70084-sec-0090"><label>3</label><title>Ethical Considerations</title><p>Inform consent was obtained and the project was approved by the Research Ethics Committee of the Centre hospitalier universitaire de Qu&#233;bec (CHUQ) under the number &#8216;Project 2012&#8211;1674, DR&#8208;002&#8211;1409&#8217;.</p></sec><sec id="msc70084-sec-0100"><label>4</label><title>Results</title><sec id="msc70084-sec-0110"><label>4.1</label><title>Characteristics of Participants</title><p>Our study included 1658 people between 1997 and 2018. The mean age of participants at the first diagnosis of low back pain was 64.1&#160;years (SD&#160;=&#160;8.3&#160;years). Participants aged 65 and over represented 57.1% of the sample. The proportion of men and women was fairly even, with 50.7% of women.</p></sec><sec id="msc70084-sec-0120"><label>4.2</label><title>Characteristics of Episodes of Non&#8208;Specific Low Back Pain</title><p>We identified 5214 episodes of non&#8208;specific low back pain, 66.1% of which occurred in people aged 65 and over, and 53.9% in women. The duration of episodes was one day in 95.9% of participants, and the maximum duration was 43&#160;days. The number of episodes per participant ranged from 1 to 66, with 44.8% of participants having a single episode and 10.6% having 7 or more. During the follow&#8208;up period, the number of people with at least one episode rose from 124 in 1997&#8211;1998 (4.2%) to 411 in 2017&#8211;2018 (13.9%). Similarly, the total number of episodes rose from 219 in 1997&#8211;1998 to 727 in 2017&#8211;2018.</p></sec><sec id="msc70084-sec-0130"><label>4.3</label><title>Descriptive Prevalence of the Pharmacological Classes</title><p>Figure&#160;<xref rid="msc70084-fig-0002" ref-type="fig">2</xref> shows that opioids were the most frequently claimed group of drugs between 1997&#8211;1998 and 2003&#8211;2004, again between 2007&#8211;2008 and 2009&#8211;2010, and in 2015&#8211;2016, with prevalences ranging from 4.1% (1997&#8211;1998) to 12.7% (2009&#8211;2010). Following opioids, myorelaxants were more frequently claimed than anticonvulsants between 1997&#8211;1998 and 2003&#8211;2004. However, from 2009 to 2010 onwards, the prevalence of anticonvulsant claims surpassed that of myorelaxants, ranging from 9.2% in 2009&#8211;2010 to 11.7% in 2017&#8211;2018. After 2001&#8211;2002, antidepressants had the lowest number of claims among the pharmacological classes.</p><fig position="float" fig-type="FIGURE" id="msc70084-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Prevalence of claims for different pharmacological classes during and 7&#160;days after an episode of non&#8208;specific low back pain, 1997 to 2018.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="MSC-23-e70084-g001.jpg"/></fig></sec><sec id="msc70084-sec-0140"><label>4.4</label><title>Trends in Drug Claims by Class Between 1997 and 2018</title><p>Figure&#160;<xref rid="msc70084-fig-0003" ref-type="fig">3.1</xref> shows a significant increase in the prevalence of opioid claims, rising from 4.1% in 1997&#8211;1998 to 12.7% in 2009&#8211;2010 (prevalence ratio (PR) per period&#160;=&#160;1.24, 95% CI: 1.09&#8211;1.41). No significant trend was observed after 2009&#8211;2010 (<italic toggle="yes">p</italic> for trend&#160;=&#160;0.2688). Claims for antidepressants (Figure&#160;<xref rid="msc70084-fig-0003" ref-type="fig">3.2</xref>) did not change significantly over time (<italic toggle="yes">p</italic> for trend&#160;=&#160;0.5508). On the other hand, the prevalence of anticonvulsant claims increased from1997&#8208;1998 to 2011&#8211;2012 (<italic toggle="yes">p</italic> for trend&#160;=&#160;0.0002; Figure&#160;<xref rid="msc70084-fig-0003" ref-type="fig">3.3</xref>), rising from 0.0% to 10.5%; the PR per period was 1.34 (95% CI: 1.15&#8211;1.57); no trend was observed after 2011&#8211;2012 (<italic toggle="yes">p</italic> for trend&#160;=&#160;0.7360). Finally, claims for myorelaxants also increased significantly between 1997&#8211;1998 and 2009&#8211;2010, with prevalences of 2.0% and 8.8%, respectively (Figure&#160;<xref rid="msc70084-fig-0003" ref-type="fig">3.4</xref>); the PR per period was 1.25 (95% CI: 1.12&#8211;1.39 between 1997&#8211;1998 and 2009&#8211;2010; Table&#160;<xref rid="msc70084-tbl-0001" ref-type="table">1</xref>).</p><fig position="float" fig-type="FIGURE" id="msc70084-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Trends in the prevalence of claims by pharmacological class during and 7&#160;days after an episode of non&#8208;specific low back pain, 1997 to 2018.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="MSC-23-e70084-g002.jpg"/></fig><table-wrap position="float" id="msc70084-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Characteristics of participants and episodes of LBP occurring in these participants between 1997 and 2018.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Characteristics</th><th align="center" valign="bottom" rowspan="1" colspan="1">Participants n (%) (<italic toggle="yes">N</italic>&#160;=&#160;1658)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Episodes of LBP n (%) (<italic toggle="yes">N</italic>&#160;=&#160;5214)</th></tr></thead><tbody valign="top"><tr><td colspan="3" align="left" valign="top" rowspan="1">Age<xref rid="msc70084-note-0006" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&lt;&#160;65&#160;years</td><td align="center" valign="top" rowspan="1" colspan="1">712 (42.9)</td><td align="center" valign="top" rowspan="1" colspan="1">1767 (33.9)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&#8805;&#160;65&#160;years</td><td align="center" valign="top" rowspan="1" colspan="1">946 (57.1)</td><td align="center" valign="top" rowspan="1" colspan="1">3447 (66.1)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Average age (standard deviation)</td><td align="center" valign="top" rowspan="1" colspan="1">64.1 (8.3)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Gender</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Women</td><td align="center" valign="top" rowspan="1" colspan="1">840 (50.7)</td><td align="center" valign="top" rowspan="1" colspan="1">2808 (53.9)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Men</td><td align="center" valign="top" rowspan="1" colspan="1">818 (49.3)</td><td align="center" valign="top" rowspan="1" colspan="1">2406 (46.1)</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Episode length</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">1&#160;day</td><td align="center" valign="top" rowspan="1" colspan="1">1590 (95.9)</td><td align="center" valign="top" rowspan="1" colspan="1">4961 (95.1)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2&#8211;43&#160;days</td><td align="center" valign="top" rowspan="1" colspan="1">68 (4.1)</td><td align="center" valign="top" rowspan="1" colspan="1">253 (4.9)</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Comorbidities before episodes of LBP</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Cancer</td><td align="center" valign="top" rowspan="1" colspan="1">42 (2.5)</td><td align="center" valign="top" rowspan="1" colspan="1">160 (3.1)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Depression only</td><td align="center" valign="top" rowspan="1" colspan="1">79 (4.8)</td><td align="center" valign="top" rowspan="1" colspan="1">366 (7.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Depression + other mental disorders&#167;</td><td align="center" valign="top" rowspan="1" colspan="1">269 (16.2)</td><td align="center" valign="top" rowspan="1" colspan="1">1080 (20.7)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Epilepsy only</td><td align="center" valign="top" rowspan="1" colspan="1">16 (1.0)</td><td align="center" valign="top" rowspan="1" colspan="1">34 (0.7)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Epilepsy + bipolar disorder</td><td align="center" valign="top" rowspan="1" colspan="1">35 (2.1)</td><td align="center" valign="top" rowspan="1" colspan="1">122 (2.3)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other musculoskeletal disorders</td><td align="center" valign="top" rowspan="1" colspan="1">290 (17.5)</td><td align="center" valign="top" rowspan="1" colspan="1">1291 (24.8)</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Number of episodes of LBP per participant</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">743 (44.8)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2 to3</td><td align="center" valign="top" rowspan="1" colspan="1">505 (30.5)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">4 to 6</td><td align="center" valign="top" rowspan="1" colspan="1">235 (14.2)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">7 to 66</td><td align="center" valign="top" rowspan="1" colspan="1">175 (10.6)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Period<xref rid="msc70084-note-0007" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">1997&#8211;1998</td><td align="center" valign="top" rowspan="1" colspan="1">124 (4.2)</td><td align="center" valign="top" rowspan="1" colspan="1">219 (4.2)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">1999&#8211;2000</td><td align="center" valign="top" rowspan="1" colspan="1">131 (4.4)</td><td align="center" valign="top" rowspan="1" colspan="1">231 (4.4)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2001&#8211;2002</td><td align="center" valign="top" rowspan="1" colspan="1">147 (5.0)</td><td align="center" valign="top" rowspan="1" colspan="1">265 (5.1)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2003&#8211;2004</td><td align="center" valign="top" rowspan="1" colspan="1">174 (5.9)</td><td align="center" valign="top" rowspan="1" colspan="1">309 (5.9)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2005&#8211;2006</td><td align="center" valign="top" rowspan="1" colspan="1">204 (6.9)</td><td align="center" valign="top" rowspan="1" colspan="1">338 (6.5)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2007&#8211;2008</td><td align="center" valign="top" rowspan="1" colspan="1">268 (9.1)</td><td align="center" valign="top" rowspan="1" colspan="1">472 (9.1)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2009&#8211;2010</td><td align="center" valign="top" rowspan="1" colspan="1">272 (9.2)</td><td align="center" valign="top" rowspan="1" colspan="1">504 (9.7)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2011&#8211;2012</td><td align="center" valign="top" rowspan="1" colspan="1">342 (11.6)</td><td align="center" valign="top" rowspan="1" colspan="1">640 (12.3)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2013&#8211;2014</td><td align="center" valign="top" rowspan="1" colspan="1">405 (13.7)</td><td align="center" valign="top" rowspan="1" colspan="1">701 (13.4)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2015&#8211;2016</td><td align="center" valign="top" rowspan="1" colspan="1">482 (16.3)</td><td align="center" valign="top" rowspan="1" colspan="1">808 (15.5)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2017&#8211;2018</td><td align="center" valign="top" rowspan="1" colspan="1">411 (13.9)</td><td align="center" valign="top" rowspan="1" colspan="1">727 (13.9)</td></tr></tbody></table><table-wrap-foot id="msc70084-ntgp-0002"><fn id="msc70084-note-0006"><label>
<sup>a</sup>
</label><p>Age: age at first medical service for LBP in periods covered by RAMQ medical insurance.</p></fn><fn id="msc70084-note-0007"><label>
<sup>b</sup>
</label><p>Period: this corresponds to the period associated with the date of diagnosis of LBP &#167;Other mental disorders: anxiety disorders, bipolar disorders and other phobic disorders; &#8208; Other musculoskeletal disorders: neck pain, shoulder pain, fibromyalgia, osteoarthritis, and arthritis; LBP: low back pain.</p></fn></table-wrap-foot></table-wrap><p>Sensitivity analyses performed with 14&#8208;day and 28&#8208;day windows after an episode of non&#8208;specific low back pain (Appendix 5 in Supporting Information&#160;<xref rid="msc70084-sup-0001" ref-type="supplementary-material">S1</xref>, Tables&#160;<xref rid="msc70084-tbl-0001" ref-type="table">1</xref> and <xref rid="msc70084-tbl-0002" ref-type="table">2</xref>) show the same results as the primary analysis using a 7&#8208;day window.</p><table-wrap position="float" id="msc70084-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Trends in the prevalence of claims by pharmacological class during and within 7&#160;days of an episode of non&#8208;specific LBP between 1997 and 2018.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th style="border-bottom:solid 1px #000000" colspan="15" align="left" valign="bottom" rowspan="1">Prevalence of claims in % (95% CI) (<italic toggle="yes">N</italic>&#160;=&#160;5214) PR (95% CI)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Variables</td><td align="center" valign="top" rowspan="1" colspan="1">1997&#8211;1998 (<italic toggle="yes">n</italic>&#160;=&#160;219)</td><td align="center" valign="top" rowspan="1" colspan="1">1999&#8211;2000 (<italic toggle="yes">n</italic>&#160;=&#160;231)</td><td align="center" valign="top" rowspan="1" colspan="1">2001&#8211;2002 (<italic toggle="yes">n</italic>&#160;=&#160;265)</td><td align="center" valign="top" rowspan="1" colspan="1">2003&#8211;2004 (<italic toggle="yes">n</italic>&#160;=&#160;309)</td><td align="center" valign="top" rowspan="1" colspan="1">2005&#8211;2006 (<italic toggle="yes">n</italic>&#160;=&#160;338)</td><td align="center" valign="top" rowspan="1" colspan="1">2007&#8211;2008 (<italic toggle="yes">n</italic>&#160;=&#160;472)</td><td align="center" valign="top" rowspan="1" colspan="1">2009&#8211;2010 (<italic toggle="yes">n</italic>&#160;=&#160;504)</td><td align="center" valign="top" rowspan="1" colspan="1">2011&#8211;2012 (<italic toggle="yes">n</italic>&#160;=&#160;640)</td><td align="center" valign="top" rowspan="1" colspan="1">2013&#8211;2014 (<italic toggle="yes">n</italic>&#160;=&#160;701)</td><td align="center" valign="top" rowspan="1" colspan="1">2015&#8211;2016 (<italic toggle="yes">n</italic>&#160;=&#160;808)</td><td align="center" valign="top" rowspan="1" colspan="1">2017&#8211;2018 (<italic toggle="yes">n</italic>&#160;=&#160;727)</td><td align="center" valign="top" rowspan="1" colspan="1">P for trend<xref rid="msc70084-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">1997&#8211;1998 to 2009&#8211;2010<xref rid="msc70084-note-0004" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">1997&#8211;1998 to 2011&#8211;2012<xref rid="msc70084-note-0005" ref-type="table-fn">
<sup>c</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Opioids</td><td align="center" valign="top" rowspan="1" colspan="1">4.1 (2.2&#8211;7.8)</td><td align="center" valign="top" rowspan="1" colspan="1">5.8 (3.0&#8211;11.2)</td><td align="center" valign="top" rowspan="1" colspan="1">5.2 (2.8&#8211;9.8)</td><td align="center" valign="top" rowspan="1" colspan="1">5.0 (2.8&#8211;8.6)</td><td align="center" valign="top" rowspan="1" colspan="1">7.3 (4.6&#8211;11.7)</td><td align="center" valign="top" rowspan="1" colspan="1">12.5 (8.1&#8211;19.3)</td><td align="center" valign="top" rowspan="1" colspan="1">12.7 (8.2&#8211;19.8)</td><td align="center" valign="top" rowspan="1" colspan="1">10.2 (7.4&#8211;14.2)</td><td align="center" valign="top" rowspan="1" colspan="1">10.0 (7.6&#8211;13.3)</td><td align="center" valign="top" rowspan="1" colspan="1">11.0 (8.5&#8211;14.0)</td><td align="center" valign="top" rowspan="1" colspan="1">9.0 (7.0&#8211;11.6)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.0135</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1.24 (1.09&#8211;1.41)</td><td align="center" valign="top" rowspan="1" colspan="1">1.15 (1.06&#8211;1.24)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Antidepressants</td><td align="center" valign="top" rowspan="1" colspan="1">0.5 (0.1&#8211;3.6)</td><td align="center" valign="top" rowspan="1" colspan="1">2.4 (0.7&#8211;8.1)</td><td align="center" valign="top" rowspan="1" colspan="1">2.4 (0.9&#8211;6.6)</td><td align="center" valign="top" rowspan="1" colspan="1">1.7 (0.7&#8211;4.0)</td><td align="center" valign="top" rowspan="1" colspan="1">1.8 (0.5&#8211;5.9)</td><td align="center" valign="top" rowspan="1" colspan="1">2.5 (1.1&#8211;6.0)</td><td align="center" valign="top" rowspan="1" colspan="1">2.6 (1.0&#8211;6.7)</td><td align="center" valign="top" rowspan="1" colspan="1">1.1 (0.5&#8211;2.3)</td><td align="center" valign="top" rowspan="1" colspan="1">1.8 (1.0&#8211;3.2)</td><td align="center" valign="top" rowspan="1" colspan="1">2.1 (1.1&#8211;4.0)</td><td align="center" valign="top" rowspan="1" colspan="1">2.6 (1.5&#8211;4.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.5508</td><td align="center" valign="top" rowspan="1" colspan="1">1.07 (0.84&#8211;1.36)</td><td align="center" valign="top" rowspan="1" colspan="1">0.98 (0.84&#8211;1.14)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anticonvulsants</td><td align="center" valign="top" rowspan="1" colspan="1">0.0 (0.0&#8211;1.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.9 (0.2&#8211;3.8)</td><td align="center" valign="top" rowspan="1" colspan="1">2.4 (0.7&#8211;7.9)</td><td align="center" valign="top" rowspan="1" colspan="1">3.7 (1.1&#8211;12.7)</td><td align="center" valign="top" rowspan="1" colspan="1">8.3 (4.3&#8211;16.2)</td><td align="center" valign="top" rowspan="1" colspan="1">5.3 (3.3&#8211;8.4)</td><td align="center" valign="top" rowspan="1" colspan="1">9.2 (6.0&#8211;14.1)</td><td align="center" valign="top" rowspan="1" colspan="1">10.5 (7.7&#8211;14.3)</td><td align="center" valign="top" rowspan="1" colspan="1">10.2 (7.5&#8211;14.0)</td><td align="center" valign="top" rowspan="1" colspan="1">8.7 (6.4&#8211;11.7)</td><td align="center" valign="top" rowspan="1" colspan="1">11.7 (9.0&#8211;15.3)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>&lt;</bold>&#160;<bold>0.0001</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1.43 (1. 16&#8211;1.76)</td><td align="center" valign="top" rowspan="1" colspan="1">1.34 (1. 15&#8211;1.57)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Myorelaxants</td><td align="center" valign="top" rowspan="1" colspan="1">2.0 (0.8&#8211;4.7)</td><td align="center" valign="top" rowspan="1" colspan="1">2.6 (1.2&#8211;5.7)</td><td align="center" valign="top" rowspan="1" colspan="1">4.4 (2.4&#8211;8.2)</td><td align="center" valign="top" rowspan="1" colspan="1">4.6 (2.8&#8211;7.6)</td><td align="center" valign="top" rowspan="1" colspan="1">6.0 (3.6&#8211;9.9)</td><td align="center" valign="top" rowspan="1" colspan="1">7.1 (4.7&#8211;10.7)</td><td align="center" valign="top" rowspan="1" colspan="1">8.8 (5.8&#8211;13.3)</td><td align="center" valign="top" rowspan="1" colspan="1">5.4 (3.8&#8211;7.7)</td><td align="center" valign="top" rowspan="1" colspan="1">6.4 (4.7&#8211;8.8)</td><td align="center" valign="top" rowspan="1" colspan="1">8.0 (6.3&#8211;10.4)</td><td align="center" valign="top" rowspan="1" colspan="1">7.0 (5.3&#8211;9.3)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.0014</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1.25 (1.12&#8211;1.39)</td><td align="center" valign="top" rowspan="1" colspan="1">1.13 (1.05&#8211;1.22)</td></tr></tbody></table><table-wrap-foot id="msc70084-ntgp-0001"><fn id="msc70084-note-0008"><p>
<italic toggle="yes">Note:</italic> The bold values indicate statistically significant trend.</p></fn><fn id="msc70084-note-0002"><p>Abbreviations: CI: confidence interval; LBP: low back pain; PR: prevalence ratio.</p></fn><fn id="msc70084-note-0003"><label>
<sup>a</sup>
</label><p>
<italic toggle="yes">p</italic> value for trend from 1997&#8211;1998 to 2017&#8211;2018 age adjusted.</p></fn><fn id="msc70084-note-0004"><label>
<sup>b</sup>
</label><p>Indicates the change in the prevalences when comparing time t and time (t&#8208;1) between 1997&#8211;1998 and 2009&#8211;2010.</p></fn><fn id="msc70084-note-0005"><label>
<sup>c</sup>
</label><p>Indicates the change in the prevalences when comparing time t and time (t&#8208;1) between 1997&#8211;1998 and 2011&#8211;2012.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="msc70084-sec-0150"><label>5</label><title>Discussion</title><p>The aim of this study was to describe changes in the prevalence of claims for opioids, antidepressants, anticonvulsants, and myorelaxants in white&#8208;collar workers presenting with one or more episodes of non&#8208;specific low back pain, using medico&#8208;administrative databases from 1997 to 2018. Our results show heterogeneous trends in the prevalence of claims across the four drug groups. Claims of opioids, anticonvulsants, and myorelaxants significant increased over time, while claims for antidepressants remained stable.</p><p>The increase in opioid claims observed up to 2010 aligns with findings from several studies on this topic (Chen et&#160;al.&#160;<xref rid="msc70084-bib-0004" ref-type="bibr">2022</xref>; Elmore et&#160;al.&#160;<xref rid="msc70084-bib-0010" ref-type="bibr">2021</xref>; Jin et&#160;al.&#160;<xref rid="msc70084-bib-0023" ref-type="bibr">2022</xref>; Piper et&#160;al.&#160;<xref rid="msc70084-bib-0039" ref-type="bibr">2018</xref>). However, no significant decrease in opioid claims was observed after 2010. This could be attributed to the 2010&#8208;2011 guidelines, which were not specific enough and generally supported opioid prescribing, offering limited guidance on when opioids should be avoided (Furlan et&#160;al.&#160;<xref rid="msc70084-bib-0014" ref-type="bibr">2010</xref>; Kahan et&#160;al.&#160;<xref rid="msc70084-bib-0024" ref-type="bibr">2011</xref> Wilson, &amp; Srivastava, 2011). On the other hand, recent studies (after 2017) have reported a decline in opioid prescribing for pain management in Canada, particularly in Qu&#233;bec (CIHI&#160;<xref rid="msc70084-bib-0006" ref-type="bibr">2019</xref>; IQVIA&#160;<xref rid="msc70084-bib-0021" ref-type="bibr">2022</xref>). This shift could be explained by the more specific 2017 Canadian guidelines that focused on enhancing patient safety while reducing opioid prescribing (Jason&#160;<xref rid="msc70084-bib-0022" ref-type="bibr">2017</xref>). One key recommendation in these guidelines was to optimise non&#8208;opioid pharmacotherapy (e.g., non&#8208;steroidal anti&#8208;inflammatory drugs) and non&#8208;pharmacological therapy over opioid use for patients with chronic non&#8208;cancer pain.</p><p>Our study is not the only one to report an increase in the use of anticonvulsants for pain management in recent years. Similar observations have been made in other countries, including the United States (Soprano et&#160;al.&#160;<xref rid="msc70084-bib-0046" ref-type="bibr">2020</xref>) and the United Kingdom (Yu et&#160;al.&#160;<xref rid="msc70084-bib-0054" ref-type="bibr">2021</xref>). Gabapentinoids (pregabalin and gabapentin) are the main anticonvulsants recently used for pain management, which could explain this increase in the use of this drug class (Bongiovanni et&#160;al.&#160;<xref rid="msc70084-bib-0001" ref-type="bibr">2023</xref>; Gingras et&#160;al.&#160;<xref rid="msc70084-bib-0015" ref-type="bibr">2019</xref>; Soni and Walters&#160;<xref rid="msc70084-bib-0045" ref-type="bibr">2019</xref>; Viniol et&#160;al.&#160;<xref rid="msc70084-bib-0052" ref-type="bibr">2019</xref>). This finding may require attention, as the side effects of these anticonvulsants are almost like those of opioids (Driot et&#160;al.&#160;<xref rid="msc70084-bib-0009" ref-type="bibr">2019</xref>; Molero et&#160;al.&#160;<xref rid="msc70084-bib-0036" ref-type="bibr">2019</xref>; Shanthanna et&#160;al.&#160;<xref rid="msc70084-bib-0043" ref-type="bibr">2017</xref>).</p><p>Antidepressants did not show any significant variation in claims during the study period. The lack of scientific evidence supporting the efficacy of this pharmacological class to treat low back pain could explain this (Turner and Denny&#160;<xref rid="msc70084-bib-0050" ref-type="bibr">1993</xref>). However, a study carried out in the United States showed an upward trend in antidepressant prescriptions for managing moderate to severe pain (Gorfinkel et&#160;al.&#160;<xref rid="msc70084-bib-0016" ref-type="bibr">2022</xref>). This study focused on the period from 2014 to 2018, in contrast to the present study, which covered a broader timeframe.</p><p>Finally, a statistically significant increase in the prevalence of myorelaxant claims was observed during the study period. These results align with those of another study that assessed trends in prescription drug use among adults in the United States (Kantor et&#160;al.&#160;<xref rid="msc70084-bib-0025" ref-type="bibr">2015</xref>). The authors reported a rise in myorelaxant use, from 1.9% in 1999&#8211;2000 to 2.5% in 2011&#8211;2012. In contrast, the prevalence figures in the present study were higher, ranging from 2.0% in 1997&#8211;1998 to 7.0% in 2017&#8211;2018, with a peak of 8.8% in 2009&#8211;2010. Our prevalence estimates are more recent, as they span up to 2017&#8211;2018, whereas the previous study covered up to 2011&#8211;2012. Other studies have also found a substantial increase in myorelaxants use, with prevalence doubling between 2005 and 2016 in people aged over 65, reaching an estimated prevalence of 22.2% in 2016 (Soprano et&#160;al.&#160;<xref rid="msc70084-bib-0046" ref-type="bibr">2020</xref>).</p><sec id="msc70084-sec-0160"><label>5.1</label><title>Strengths and Limitations</title><sec id="msc70084-sec-0170"><label>5.1.1</label><title>Strengths</title><p>We had access to medico&#8208;administrative data that provided detailed records of drug claims for the individuals included in the study, allowing for precise identification of drugs dispensed in pharmacies. This contrasts with self&#8208;reported data, which could be affected by information bias. The availability of data over a long period (from 1997 to 2018) and covering a large number of participants further enabled us to assess trends in drug claims across several classes of drugs over time.</p></sec><sec id="msc70084-sec-0180"><label>5.1.2</label><title>Limitations</title><p>One of the main limitations of this study is the absence of indication for the medications claimed in the RAMQ database. To address this, we inferred that the drugs claimed were related to the medical visit based on the dispensing date. This approach may have resulted in an underestimation of our prevalences. However, sensitivity analyses performed using 14&#8208;day and 28&#8208;day windows after the episode of low back pain showed trends similar to those observed with a 7&#8208;day window. Additionally, several studies examining prescribed drugs for a given condition have employed similar inferential methods with varying time intervals (Fortin et&#160;al.&#160;<xref rid="msc70084-bib-0013" ref-type="bibr">2022</xref>; Lacasse et&#160;al.&#160;<xref rid="msc70084-bib-0030" ref-type="bibr">2016</xref>). Another potential limitation is the inclusion of participants whose low back pain occurred during a period of eligibility for RAMQ drug insurance, which may have introduced a selection bias. While the RAMQ drug insurance plan predominantly covers people aged 65 and over, those under 65 are generally covered by private insurance, for which we lack data. Nevertheless, the estimates for people aged 65 and over, particularly for opioids, are largely consistent with those for the general population of Qu&#233;bec across all conditions (Pierre and Daniel&#160;<xref rid="msc70084-bib-0038" ref-type="bibr">2023</xref>). This finding supports the external validity of our results for the entire adult population in Qu&#233;bec.</p></sec></sec></sec><sec id="msc70084-sec-0190"><label>6</label><title>Conclusions</title><p>Analysis of trends in drug claims for non&#8208;specific low back pain showed significant shifts in prescribing behaviour, with a general upward trend across all pharmacological classes, except for antidepressants. While opioids remained the most frequently prescribed class for managing low back pain, our study showed a notable increase in the prescription of anticonvulsants for this condition in the province of Qu&#233;bec. More recent data would be necessary to confirm these findings and potentially uncover new insights regarding the use of these drugs classes.</p></sec><sec id="msc70084-sec-0200"><title>Author Contributions</title><p>C.E.D. initiated the study, provided access to data, discussed the results and led the writing of the manuscript. A.L. designed the study, performed the analysis, discussed the results, wrote and reviewed the manuscript under the supervision of C.E.D. C.S.&#160;helped in the definition of drugs algorithms and the exploitation of medico&#8208;administrative data and discussed the results. All the authors discussed core ideas, participated in interpretation of data, and contributed to the writing of the final paper. All authors have read and approved the submitted version of the manuscript.</p></sec><sec id="msc70084-sec-0230"><title>Consent</title><p>All participants signed an informed consent form.</p></sec><sec sec-type="COI-statement" id="msc70084-sec-0240"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="msc70084-sup-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information S1</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="MSC-23-e70084-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="msc70084-sec-0220"><title>Acknowledgements</title><p>Thanks to Dr. Xavier Trudel for sharing access to the <italic toggle="yes">PROspective Qu&#233;bec (PROQ) Study on Work and Health</italic> data, Ms. Caty Blanchette for help with the analyses, and all the participants of this study.</p></ack><sec sec-type="data-availability" id="msc70084-sec-0260"><title>Data Availability Statement</title><p>The SAS program is available upon request. This study was not preregistered in an institutional registry. The protocol and the datasets for this study are available from the corresponding author on reasonable request and under certain conditions.</p></sec><ref-list content-type="cited-references" id="msc70084-bibl-0001"><title>References</title><ref id="msc70084-bib-0001"><mixed-citation publication-type="journal" id="msc70084-cit-0001"><string-name name-style="western"><surname>Bongiovanni</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Gan</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Finlayson</surname></string-name>, et&#160;al. <year>2023</year>. &#8220;<article-title>Trends in the Use of Gabapentinoids and Opioids in the Postoperative Period Among Older Adults</article-title>.&#8221; <source>JAMA Network Open</source><volume>6</volume>, no. <issue>6</issue>: <elocation-id>e2318626</elocation-id>. <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.18626</pub-id>.<pub-id pub-id-type="pmid">37326989</pub-id><pub-id pub-id-type="pmcid">PMC10276300</pub-id></mixed-citation></ref><ref id="msc70084-bib-0002"><mixed-citation publication-type="journal" id="msc70084-cit-0002"><string-name name-style="western"><surname>Bussi&#232;res</surname>, <given-names>A. E.</given-names></string-name>, <string-name name-style="western"><given-names>J. A.</given-names><surname>Taylor</surname></string-name>, and <string-name name-style="western"><given-names>C.</given-names><surname>Peterson</surname></string-name>. <year>2008</year>. &#8220;<article-title>Diagnostic Imaging Practice Guidelines for Musculoskeletal Complaints in Adults&#8208;An Evidence&#8208;Based Approach&#8208;Part 3: Spinal Disorders</article-title>.&#8221; <source>Journal of Manipulative and Physiological Therapeutics</source><volume>31</volume>, no. <issue>1</issue>: <fpage>33</fpage>&#8211;<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmpt.2007.11.003</pub-id>.<pub-id pub-id-type="pmid">18308153</pub-id></mixed-citation></ref><ref id="msc70084-bib-0003"><mixed-citation publication-type="journal" id="msc70084-cit-0003"><string-name name-style="western"><surname>Chaves</surname>, <given-names>T. V.</given-names></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Wilffert</surname></string-name>, and <string-name name-style="western"><given-names>Z. M.</given-names><surname>Sanchez</surname></string-name>. <year>2022</year>. &#8220;<article-title>Overdoses and Deaths Related to the Use of Ketamine and its Analogues: A Systematic Review</article-title>.&#8221; <source>American Journal of Drug and Alcohol Abuse</source><volume>49</volume>, no. <issue>2</issue>: <fpage>1</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1080/00952990.2022.2132506</pub-id>.<pub-id pub-id-type="pmid">36410032</pub-id></mixed-citation></ref><ref id="msc70084-bib-0004"><mixed-citation publication-type="journal" id="msc70084-cit-0004"><string-name name-style="western"><surname>Chen</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Spillane</surname></string-name>, <string-name name-style="western"><given-names>M. S.</given-names><surname>Shiels</surname></string-name>, et&#160;al. <year>2022</year>. &#8220;<article-title>Trends in Opioid Use Among Cancer Patients in the United States: 2013&#8208;2018</article-title>.&#8221; <source>JNCI Cancer Spectrum</source><volume>6</volume>, no. <issue>1</issue>. <pub-id pub-id-type="doi">10.1093/jncics/pkab095</pub-id>.<pub-id pub-id-type="pmcid">PMC8793171</pub-id><pub-id pub-id-type="pmid">35098020</pub-id></mixed-citation></ref><ref id="msc70084-bib-0005"><mixed-citation publication-type="journal" id="msc70084-cit-0005"><string-name name-style="western"><surname>Chou</surname>, <given-names>R.</given-names></string-name>, and <string-name name-style="western"><given-names>L. H.</given-names><surname>Huffman</surname></string-name>. <year>2007</year>. &#8220;<article-title>Medications for Acute and Chronic Low Back Pain: A Review of the Evidence for an American Pain Society/American College of Physicians Clinical Practice Guideline</article-title>.&#8221; <source>Annals of Internal Medicine</source><volume>147</volume>, no. <issue>7</issue>: <fpage>505</fpage>&#8211;<lpage>514</lpage>. <pub-id pub-id-type="doi">10.7326/0003-4819-147-7-200710020-00008</pub-id>.<pub-id pub-id-type="pmid">17909211</pub-id></mixed-citation></ref><ref id="msc70084-bib-0006"><mixed-citation publication-type="miscellaneous" id="msc70084-cit-0006"><collab collab-type="authors">CIHI</collab>
. (<year>2019</year>). &#8220;<article-title>Opioid Prescribing in Canada: How Are Practices Changing? Ottawa</article-title>&#8221;.</mixed-citation></ref><ref id="msc70084-bib-0007"><mixed-citation publication-type="miscellaneous" id="msc70084-cit-0007"><collab collab-type="authors">CIHI</collab>
. <year>2023</year>. &#8220;<article-title>Mesures f&#233;d&#233;rales sur les opioides &#224; ce jour</article-title>.&#8221; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.canada.ca/content/dam/hc-sc/documents/services/substance-use/problematic-prescription-drug-use/opioids/responding-canada-opioid-crisis/federal-actions/mesures-federales-apercu.pdf.Consult%E9le08-02-2023" ext-link-type="uri">https://www.canada.ca/content/dam/hc&#8208;sc/documents/services/substance&#8208;use/problematic&#8208;prescription&#8208;drug&#8208;use/opioids/responding&#8208;canada&#8208;opioid&#8208;crisis/federal&#8208;actions/mesures&#8208;federales&#8208;apercu.pdf.Consult&#233;le08&#8208;02&#8208;2023</ext-link>.</mixed-citation></ref><ref id="msc70084-bib-0008"><mixed-citation publication-type="journal" id="msc70084-cit-0008"><string-name name-style="western"><surname>Darke</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Duflou</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Peacock</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Farrell</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Lappin</surname></string-name>. <year>2022</year>. &#8220;<article-title>Characteristics of Fatal Gabapentinoid&#8208;Related Poisoning in Australia, 2000&#8208;2020</article-title>.&#8221; <source>Clinical Toxicology</source><volume>60</volume>, no. <issue>3</issue>: <fpage>304</fpage>&#8211;<lpage>310</lpage>. <pub-id pub-id-type="doi">10.1080/15563650.2021.1965159</pub-id>.<pub-id pub-id-type="pmid">34402696</pub-id></mixed-citation></ref><ref id="msc70084-bib-0009"><mixed-citation publication-type="journal" id="msc70084-cit-0009"><string-name name-style="western"><surname>Driot</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Jouanjus</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Oustric</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Dupouy</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Lapeyre&#8208;Mestre</surname></string-name>. <year>2019</year>. &#8220;<article-title>Patterns of Gabapentin and Pregabalin Use and Misuse: Results of a Population&#8208;Based Cohort Study in France</article-title>.&#8221; <source>British Journal of Clinical Pharmacology</source><volume>85</volume>, no. <issue>6</issue>: <fpage>1260</fpage>&#8211;<lpage>1269</lpage>. <pub-id pub-id-type="doi">10.1111/bcp.13892</pub-id>.<pub-id pub-id-type="pmid">30737829</pub-id><pub-id pub-id-type="pmcid">PMC6533441</pub-id></mixed-citation></ref><ref id="msc70084-bib-0010"><mixed-citation publication-type="journal" id="msc70084-cit-0010"><string-name name-style="western"><surname>Elmore</surname>, <given-names>A. L.</given-names></string-name>, <string-name name-style="western"><given-names>O. O.</given-names><surname>Omofuma</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Sevoyan</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Richard</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Liu</surname></string-name>. <year>2021</year>. &#8220;<article-title>Prescription Opioid Use Among Women of Reproductive Age in the United States: NHANES, 2003&#8208;2018</article-title>.&#8221; <source>Preventive Medicine</source><volume>153</volume>: <elocation-id>106846</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.ypmed.2021.106846</pub-id>.<pub-id pub-id-type="pmid">34653502</pub-id><pub-id pub-id-type="pmcid">PMC8595805</pub-id></mixed-citation></ref><ref id="msc70084-bib-0011"><mixed-citation publication-type="journal" id="msc70084-cit-0011"><string-name name-style="western"><surname>Encinosa</surname>, <given-names>W.</given-names></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Bernard</surname></string-name>, and <string-name name-style="western"><given-names>T. M.</given-names><surname>Selden</surname></string-name>. <year>2022</year>. &#8220;<article-title>Opioid and Non&#8208;opioid Analgesic Prescribing Before and After the CDC's 2016 Opioid Guideline</article-title>.&#8221; <source>Int J Health Econ Manag</source><volume>22</volume>, no. <issue>1</issue>: <fpage>1</fpage>&#8211;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1007/s10754-021-09307-4</pub-id>.<pub-id pub-id-type="pmid">33963977</pub-id><pub-id pub-id-type="pmcid">PMC8105705</pub-id></mixed-citation></ref><ref id="msc70084-bib-0012"><mixed-citation publication-type="journal" id="msc70084-cit-0012"><string-name name-style="western"><surname>Fields</surname>, <given-names>H. L.</given-names></string-name><year>2011</year>. &#8220;<article-title>The Doctor's Dilemma: Opiate Analgesics and Chronic Pain</article-title>.&#8221; <source>Neuron</source><volume>69</volume>, no. <issue>4</issue>: <fpage>591</fpage>&#8211;<lpage>594</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2011.02.001</pub-id>.<pub-id pub-id-type="pmid">21338871</pub-id><pub-id pub-id-type="pmcid">PMC3073133</pub-id></mixed-citation></ref><ref id="msc70084-bib-0013"><mixed-citation publication-type="journal" id="msc70084-cit-0013"><string-name name-style="western"><surname>Fortin</surname>, <given-names>&#201;.</given-names></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Sirois</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Quach</surname></string-name>, et&#160;al. <year>2022</year>. &#8220;<article-title>Chronic Diseases and Variations in Rates of Antimicrobial Use in the Community: A Population&#8208;Based Analysis of Linked Administrative Data in Quebec, Canada, 2002&#8208;2017</article-title>.&#8221; <source>CMAJ Open</source><volume>10</volume>, no. <issue>3</issue>: <fpage>E831</fpage>&#8211;<lpage>e840</lpage>. <pub-id pub-id-type="doi">10.9778/cmajo.20210258</pub-id>.<pub-id pub-id-type="pmcid">PMC9578751</pub-id><pub-id pub-id-type="pmid">36167418</pub-id></mixed-citation></ref><ref id="msc70084-bib-0014"><mixed-citation publication-type="journal" id="msc70084-cit-0014"><string-name name-style="western"><surname>Furlan</surname>, <given-names>A. D.</given-names></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Reardon</surname></string-name>, and <string-name name-style="western"><given-names>C.</given-names><surname>Weppler</surname></string-name>. <year>2010</year>. &#8220;<article-title>Opioids for Chronic Noncancer Pain: A New Canadian Practice Guideline</article-title>.&#8221; <source>Canadian Medical Association Journal</source><volume>182</volume>, no. <issue>9</issue>: <fpage>923</fpage>&#8211;<lpage>930</lpage>. <pub-id pub-id-type="doi">10.1503/cmaj.100187</pub-id>.<pub-id pub-id-type="pmid">20439443</pub-id><pub-id pub-id-type="pmcid">PMC2882451</pub-id></mixed-citation></ref><ref id="msc70084-bib-0015"><mixed-citation publication-type="journal" id="msc70084-cit-0015"><string-name name-style="western"><surname>Gingras</surname>, <given-names>M. A.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Lieu</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Papillon&#8208;Ferland</surname></string-name>, <string-name name-style="western"><given-names>T. C.</given-names><surname>Lee</surname></string-name>, and <string-name name-style="western"><given-names>E. G.</given-names><surname>McDonald</surname></string-name>. <year>2019</year>. &#8220;<article-title>Retrospective Cohort Study of the Prevalence of Off&#8208;Label Gabapentinoid Prescriptions in Hospitalized Medical Patients</article-title>.&#8221; <source>Journal of Hospital Medicine</source><volume>14</volume>, no. <issue>9</issue>: <fpage>547</fpage>&#8211;<lpage>550</lpage>. <pub-id pub-id-type="doi">10.12788/jhm.3203</pub-id>.<pub-id pub-id-type="pmid">31112498</pub-id><pub-id pub-id-type="pmcid">PMC6715050</pub-id></mixed-citation></ref><ref id="msc70084-bib-0016"><mixed-citation publication-type="journal" id="msc70084-cit-0016"><string-name name-style="western"><surname>Gorfinkel</surname>, <given-names>L. R.</given-names></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Hasin</surname></string-name>, <string-name name-style="western"><given-names>A. J.</given-names><surname>Saxon</surname></string-name>, et&#160;al. <year>2022</year>. &#8220;<article-title>Trends in Prescriptions for Non&#8208;opioid Pain Medications Among U.S. Adults With Moderate or Severe Pain, 2014&#8208;2018</article-title>.&#8221; <source>Journal of Pain</source><volume>23</volume>, no. <issue>7</issue>: <fpage>1187</fpage>&#8211;<lpage>1195</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpain.2022.01.006</pub-id>.<pub-id pub-id-type="pmid">35143969</pub-id><pub-id pub-id-type="pmcid">PMC9271556</pub-id></mixed-citation></ref><ref id="msc70084-bib-0017"><mixed-citation publication-type="journal" id="msc70084-cit-0017"><string-name name-style="western"><surname>Hancocks</surname>, <given-names>S.</given-names></string-name><year>2019</year>. &#8220;<article-title>The Opioid Crisis in the USA</article-title>.&#8221; <source>British Dental Journal</source><volume>226</volume>, no. <issue>11</issue>: <fpage>815</fpage>. <pub-id pub-id-type="doi">10.1038/s41415-019-0420-6</pub-id>.<pub-id pub-id-type="pmid">31203310</pub-id></mixed-citation></ref><ref id="msc70084-bib-0018"><mixed-citation publication-type="journal" id="msc70084-cit-0018"><string-name name-style="western"><surname>Hornberger</surname>, <given-names>J.</given-names></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Chhatwal</surname></string-name>. <year>2021</year>. &#8220;<article-title>Opioid Misuse: A Global Crisis</article-title>.&#8221; <source>Value in Health</source><volume>24</volume>, no. <issue>2</issue>: <fpage>145</fpage>&#8211;<lpage>146</lpage>. <pub-id pub-id-type="doi">10.1016/j.jval.2020.12.003</pub-id>.<pub-id pub-id-type="pmid">33518020</pub-id></mixed-citation></ref><ref id="msc70084-bib-0019"><mixed-citation publication-type="journal" id="msc70084-cit-0019"><string-name name-style="western"><surname>Hwang</surname>, <given-names>C. S.</given-names></string-name>, <string-name name-style="western"><given-names>E. M.</given-names><surname>Kang</surname></string-name>, <string-name name-style="western"><given-names>C. J.</given-names><surname>Kornegay</surname></string-name>, <string-name name-style="western"><given-names>J. A.</given-names><surname>Staffa</surname></string-name>, <string-name name-style="western"><given-names>C. M.</given-names><surname>Jones</surname></string-name>, and <string-name name-style="western"><given-names>J. K.</given-names><surname>McAninch</surname></string-name>. <year>2016</year>. &#8220;<article-title>Trends in the Concomitant Prescribing of Opioids and Benzodiazepines, 2002&#8208;2014</article-title>.&#8221; <source>American Journal of Preventive Medicine</source><volume>51</volume>, no. <issue>2</issue>: <fpage>151</fpage>&#8211;<lpage>160</lpage>. <pub-id pub-id-type="doi">10.1016/j.amepre.2016.02.014</pub-id>.<pub-id pub-id-type="pmid">27079639</pub-id></mixed-citation></ref><ref id="msc70084-bib-0020"><mixed-citation publication-type="miscellaneous" id="msc70084-cit-0020"><collab collab-type="authors">IQVIA</collab>
. <year>2020</year>. &#8220;<article-title>Prescription Opioid Trends in the United States MEASURING and UNDERSTANDING PROGRESS IN the OPIOID CRISIS, December 2020</article-title>.&#8221; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.iqvia.com/insights/the-iqvia-institute/reports/prescription-opioid-trends-in-the-united-states" ext-link-type="uri">https://www.iqvia.com/insights/the&#8208;iqvia&#8208;institute/reports/prescription&#8208;opioid&#8208;trends&#8208;in&#8208;the&#8208;united&#8208;states</ext-link>.</mixed-citation></ref><ref id="msc70084-bib-0021"><mixed-citation publication-type="miscellaneous" id="msc70084-cit-0021"><collab collab-type="authors">IQVIA</collab>
. <year>2022</year>. &#8220;<article-title>Prescription Opioid Trends in Canada (2022): An Independent IQVIA Report on Measuring and Understanding the Use of Prescription Opioids Dispensed from 2019 to 2021</article-title>.&#8221; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.iqvia.com/-/media/iqvia/pdfs/canada/white-paper/prescriptionopioidtrendsincanada_report_en.pdf" ext-link-type="uri">https://www.iqvia.com/&#8208;/media/iqvia/pdfs/canada/white&#8208;paper/prescriptionopioidtrendsincanada_report_en.pdf</ext-link>.</mixed-citation></ref><ref id="msc70084-bib-0022"><mixed-citation publication-type="miscellaneous" id="msc70084-cit-0022"><string-name name-style="western"><surname>Jason</surname>, <given-names>B.</given-names></string-name><year>2017</year>. &#8220;<article-title>Lignes directrices canadiennes relatives &#224; l&#8217;utilisation des opio&#239;des pour le traitement de la douleur chronique non canc&#233;reuse, &#233;dition 2017</article-title>.&#8221; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cma.ca/sites/default/files/2018-11/PDFofnewFrenchguideline28sept2017.pdf" ext-link-type="uri">https://www.cma.ca/sites/default/files/2018&#8208;11/PDFofnewFrenchguideline28sept2017.pdf</ext-link>.</mixed-citation></ref><ref id="msc70084-bib-0023"><mixed-citation publication-type="journal" id="msc70084-cit-0023"><string-name name-style="western"><surname>Jin</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><given-names>S. H.</given-names><surname>Vermund</surname></string-name>, and <string-name name-style="western"><given-names>Y.</given-names><surname>Zhang</surname></string-name>. <year>2022</year>. &#8220;<article-title>Trends in Prescription Opioid Use in Motor Vehicle Crash Injuries in the United States: 2014&#8208;2018</article-title>.&#8221; <source>International Journal of Environmental Research and Public Health</source><volume>19</volume>, no. <issue>21</issue>: <elocation-id>14445</elocation-id>. <pub-id pub-id-type="doi">10.3390/ijerph192114445</pub-id>.<pub-id pub-id-type="pmid">36361324</pub-id><pub-id pub-id-type="pmcid">PMC9657604</pub-id></mixed-citation></ref><ref id="msc70084-bib-0024"><mixed-citation publication-type="journal" id="msc70084-cit-0024"><string-name name-style="western"><surname>Kahan</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Mailis&#8208;Gagnon</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Wilson</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Srivastava</surname></string-name>. <year>2011</year>. &#8220;<article-title>Canadian Guideline for Safe and Effective Use of Opioids for Chronic Noncancer Pain</article-title>.&#8221; <source>Clinical summary for family physicians. Part 1: general population</source><volume>57</volume>, no. <issue>11</issue>: <fpage>1257</fpage>&#8211;<lpage>1266</lpage>: Retrieved from. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cfp.ca/content/cfp/57/11/1257.full.pdf" ext-link-type="uri">https://www.cfp.ca/content/cfp/57/11/1257.full.pdf</ext-link>.<pub-id pub-id-type="pmcid">PMC3215602</pub-id><pub-id pub-id-type="pmid">22084455</pub-id></mixed-citation></ref><ref id="msc70084-bib-0025"><mixed-citation publication-type="journal" id="msc70084-cit-0025"><string-name name-style="western"><surname>Kantor</surname>, <given-names>E. D.</given-names></string-name>, <string-name name-style="western"><given-names>C. D.</given-names><surname>Rehm</surname></string-name>, <string-name name-style="western"><given-names>J. S.</given-names><surname>Haas</surname></string-name>, <string-name name-style="western"><given-names>A. T.</given-names><surname>Chan</surname></string-name>, and <string-name name-style="western"><given-names>E. L.</given-names><surname>Giovannucci</surname></string-name>. <year>2015</year>. &#8220;<article-title>Trends in Prescription Drug Use Among Adults in the United States from 1999&#8208;2012</article-title>.&#8221; <source>JAMA</source><volume>314</volume>, no. <issue>17</issue>: <fpage>1818</fpage>&#8211;<lpage>1831</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2015.13766</pub-id>.<pub-id pub-id-type="pmid">26529160</pub-id><pub-id pub-id-type="pmcid">PMC4752169</pub-id></mixed-citation></ref><ref id="msc70084-bib-0026"><mixed-citation publication-type="journal" id="msc70084-cit-0026"><string-name name-style="western"><surname>Khan</surname>, <given-names>N. F.</given-names></string-name>, <string-name name-style="western"><given-names>B. T.</given-names><surname>Bateman</surname></string-name>, <string-name name-style="western"><given-names>J. E.</given-names><surname>Landon</surname></string-name>, and <string-name name-style="western"><given-names>J. J.</given-names><surname>Gagne</surname></string-name>. <year>2019</year>. &#8220;<article-title>Association of Opioid Overdose With Opioid Prescriptions to Family Members</article-title>.&#8221; <source>JAMA Internal Medicine</source><volume>179</volume>, no. <issue>9</issue>: <fpage>1186</fpage>&#8211;<lpage>1192</lpage>. <pub-id pub-id-type="doi">10.1001/jamainternmed.2019.1064</pub-id>.<pub-id pub-id-type="pmid">31233088</pub-id><pub-id pub-id-type="pmcid">PMC6593630</pub-id></mixed-citation></ref><ref id="msc70084-bib-0027"><mixed-citation publication-type="journal" id="msc70084-cit-0027"><string-name name-style="western"><surname>Knadler</surname>, <given-names>M. P.</given-names></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Lobo</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Chappell</surname></string-name>, and <string-name name-style="western"><given-names>R.</given-names><surname>Bergstrom</surname></string-name>. <year>2011</year>. &#8220;<article-title>Duloxetine: Clinical Pharmacokinetics and Drug Interactions</article-title>.&#8221; <source>Clinical Pharmacokinetics</source><volume>50</volume>, no. <issue>5</issue>: <fpage>281</fpage>&#8211;<lpage>294</lpage>. <pub-id pub-id-type="doi">10.2165/11539240-000000000-00000</pub-id>.<pub-id pub-id-type="pmid">21366359</pub-id></mixed-citation></ref><ref id="msc70084-bib-0028"><mixed-citation publication-type="journal" id="msc70084-cit-0028"><string-name name-style="western"><surname>Krausz</surname>, <given-names>R. M.</given-names></string-name>, <string-name name-style="western"><given-names>J. N.</given-names><surname>Westenberg</surname></string-name>, and <string-name name-style="western"><given-names>K.</given-names><surname>Ziafat</surname></string-name>. <year>2021</year>. &#8220;<article-title>The Opioid Overdose Crisis as a Global Health Challenge</article-title>.&#8221; <source>Current Opinion in Psychiatry</source><volume>34</volume>, no. <issue>4</issue>: <fpage>405</fpage>&#8211;<lpage>412</lpage>. <pub-id pub-id-type="doi">10.1097/yco.0000000000000712</pub-id>.<pub-id pub-id-type="pmid">33901060</pub-id></mixed-citation></ref><ref id="msc70084-bib-0029"><mixed-citation publication-type="journal" id="msc70084-cit-0029"><string-name name-style="western"><surname>Kreiner</surname>, <given-names>D. S.</given-names></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Matz</surname></string-name>, <string-name name-style="western"><given-names>C. M.</given-names><surname>Bono</surname></string-name>, et&#160;al. <year>2020</year>. &#8220;<article-title>Guideline Summary Review: An Evidence&#8208;Based Clinical Guideline for the Diagnosis and Treatment of Low Back Pain</article-title>.&#8221; <source>Spine Journal</source><volume>20</volume>, no. <issue>7</issue>: <fpage>998</fpage>&#8211;<lpage>1024</lpage>. <pub-id pub-id-type="doi">10.1016/j.spinee.2020.04.006</pub-id>.<pub-id pub-id-type="pmid">32333996</pub-id></mixed-citation></ref><ref id="msc70084-bib-0030"><mixed-citation publication-type="journal" id="msc70084-cit-0030"><string-name name-style="western"><surname>Lacasse</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Ware</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Bourgault</surname></string-name>, et&#160;al. <year>2016</year>. &#8220;<article-title>Accuracy of Self&#8208;Reported Prescribed Analgesic Medication Use: Linkage Between the Quebec Pain Registry and the Quebec Administrative Prescription Claims Databases</article-title>.&#8221; <source>Clinical Journal of Pain</source><volume>32</volume>, no. <issue>2</issue>: <fpage>95</fpage>&#8211;<lpage>102</lpage>. <pub-id pub-id-type="doi">10.1097/AJP.0000000000000248</pub-id>.<pub-id pub-id-type="pmid">25924096</pub-id></mixed-citation></ref><ref id="msc70084-bib-0031"><mixed-citation publication-type="journal" id="msc70084-cit-0031"><string-name name-style="western"><surname>Lalic</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Ilomaki</surname></string-name>, <string-name name-style="western"><given-names>J. S.</given-names><surname>Bell</surname></string-name>, <string-name name-style="western"><given-names>M. J.</given-names><surname>Korhonen</surname></string-name>, and <string-name name-style="western"><given-names>N.</given-names><surname>Gisev</surname></string-name>. <year>2019</year>. &#8220;<article-title>Prevalence and Incidence of Prescription Opioid Analgesic Use in Australia</article-title>.&#8221; <source>British Journal of Clinical Pharmacology</source><volume>85</volume>, no. <issue>1</issue>: <fpage>202</fpage>&#8211;<lpage>215</lpage>. <pub-id pub-id-type="doi">10.1111/bcp.13792</pub-id>.<pub-id pub-id-type="pmid">30338545</pub-id><pub-id pub-id-type="pmcid">PMC6303244</pub-id></mixed-citation></ref><ref id="msc70084-bib-0032"><mixed-citation publication-type="journal" id="msc70084-cit-0032"><string-name name-style="western"><surname>Lev</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><given-names>O.</given-names><surname>Lee</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Petro</surname></string-name>, et&#160;al. <year>2016</year>. &#8220;<article-title>Who is prescribing controlled medications to patients who die of prescription drug abuse?</article-title>&#8221; <source>American Journal of Emergency Medicine</source><volume>34</volume>, no. <issue>1</issue>: <fpage>30</fpage>&#8211;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajem.2015.09.003</pub-id>.<pub-id pub-id-type="pmid">26476578</pub-id></mixed-citation></ref><ref id="msc70084-bib-0033"><mixed-citation publication-type="journal" id="msc70084-cit-0033"><string-name name-style="western"><surname>Ly</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Sirois</surname></string-name>, and <string-name name-style="western"><given-names>C. E.</given-names><surname>Dionne</surname></string-name>. <year>2023</year>. &#8220;<article-title>Sensitivity and Specificity of Algorithms for the Identification of Non&#8208;Specific Low Back Pain in Medico&#8208;Administrative Databases</article-title>.&#8221; <source>Pain</source><volume>164</volume>, no. <issue>7</issue>: <fpage>1600</fpage>&#8211;<lpage>1607</lpage>. <pub-id pub-id-type="doi">10.1097/j.pain.0000000000002861</pub-id>.<pub-id pub-id-type="pmid">36728479</pub-id></mixed-citation></ref><ref id="msc70084-bib-0034"><mixed-citation publication-type="journal" id="msc70084-cit-0034"><string-name name-style="western"><surname>Manchikanti</surname>, <given-names>L.</given-names></string-name>, and <string-name name-style="western"><given-names>A. D.</given-names><surname>Kaye</surname></string-name>. <year>2016</year>. &#8220;<article-title>Analysis of prescription patterns in opioid deaths shows startling findings: Re: Lev R, Lee O, Petro S, Lucas J, Castillo EM, Vilke GM, Coyne CJ. Who is prescribing controlled medications to patients who die of prescription drug abuse?. 2016 Jan.;34(1):30&#8208;5</article-title>.&#8221; <source>American Journal of Emergency Medicine</source><volume>34</volume>, no. <issue>4</issue>: <fpage>748</fpage>&#8211;<lpage>749</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajem.2016.01.035</pub-id>.<pub-id pub-id-type="pmid">26899400</pub-id></mixed-citation></ref><ref id="msc70084-bib-0035"><mixed-citation publication-type="journal" id="msc70084-cit-0035"><string-name name-style="western"><surname>Meng</surname>, <given-names>X.</given-names></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>D'Arcy</surname></string-name>, and <string-name name-style="western"><given-names>R.</given-names><surname>Tempier</surname></string-name>. <year>2013</year>. &#8220;<article-title>Trends in Psychotropic Use in Saskatchewan from 1983 to 2007</article-title>.&#8221; <source>Canadian Journal of Psychiatry</source><volume>58</volume>, no. <issue>7</issue>: <fpage>426</fpage>&#8211;<lpage>431</lpage>. <pub-id pub-id-type="doi">10.1177/070674371305800708</pub-id>.<pub-id pub-id-type="pmid">23870725</pub-id></mixed-citation></ref><ref id="msc70084-bib-0036"><mixed-citation publication-type="journal" id="msc70084-cit-0036"><string-name name-style="western"><surname>Molero</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Larsson</surname></string-name>, <string-name name-style="western"><given-names>B. M.</given-names><surname>D'Onofrio</surname></string-name>, <string-name name-style="western"><given-names>D. J.</given-names><surname>Sharp</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Fazel</surname></string-name>. <year>2019</year>. &#8220;<article-title>Associations Between Gabapentinoids and Suicidal Behaviour, Unintentional Overdoses, Injuries, Road Traffic Incidents, and Violent Crime: Population Based Cohort Study in Sweden</article-title>.&#8221; <source>BMJ</source><volume>365</volume>: <elocation-id>l2147</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmj.l2147</pub-id>.<pub-id pub-id-type="pmid">31189556</pub-id><pub-id pub-id-type="pmcid">PMC6559335</pub-id></mixed-citation></ref><ref id="msc70084-bib-0037"><mixed-citation publication-type="journal" id="msc70084-cit-0037"><string-name name-style="western"><surname>Noordam</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Aarts</surname></string-name>, <string-name name-style="western"><given-names>K. M.</given-names><surname>Verhamme</surname></string-name>, <string-name name-style="western"><given-names>M. C.</given-names><surname>Sturkenboom</surname></string-name>, <string-name name-style="western"><given-names>B. H.</given-names><surname>Stricker</surname></string-name>, and <string-name name-style="western"><given-names>L. E.</given-names><surname>Visser</surname></string-name>. <year>2015</year>. &#8220;<article-title>Prescription and Indication Trends of Antidepressant Drugs in the Netherlands between 1996 and 2012: A Dynamic Population&#8208;Based Study</article-title>.&#8221; <source>European Journal of Clinical Pharmacology</source><volume>71</volume>, no. <issue>3</issue>: <fpage>369</fpage>&#8211;<lpage>375</lpage>. <pub-id pub-id-type="doi">10.1007/s00228-014-1803-x</pub-id>.<pub-id pub-id-type="pmid">25560052</pub-id></mixed-citation></ref><ref id="msc70084-bib-0038"><mixed-citation publication-type="miscellaneous" id="msc70084-cit-0038"><string-name name-style="western"><surname>Pierre</surname>, <given-names>S. M.</given-names></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Daniel</surname></string-name>. <year>2023</year>. &#8220;<article-title>Prescription Opioid Trends in Canada an Independent IQVIA Report on Measuring and Understanding the Use of Prescription Opioids Dispensed in 2015 and 2020</article-title>.&#8221; Consult&#233; le 12 02 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.iqvia.com/locations/canada/library/white-papers/prescription-opioid-trends-in-canada" ext-link-type="uri">https://www.iqvia.com/locations/canada/library/white&#8208;papers/prescription&#8208;opioid&#8208;trends&#8208;in&#8208;canada</ext-link>.</mixed-citation></ref><ref id="msc70084-bib-0039"><mixed-citation publication-type="journal" id="msc70084-cit-0039"><string-name name-style="western"><surname>Piper</surname>, <given-names>B. J.</given-names></string-name>, <string-name name-style="western"><given-names>D. T.</given-names><surname>Shah</surname></string-name>, <string-name name-style="western"><given-names>O. M.</given-names><surname>Simoyan</surname></string-name>, <string-name name-style="western"><given-names>K. L.</given-names><surname>McCall</surname></string-name>, and <string-name name-style="western"><given-names>S. D.</given-names><surname>Nichols</surname></string-name>. <year>2018</year>. &#8220;<article-title>Trends in Medical Use of Opioids in the U.S., 2006&#8208;2016</article-title>.&#8221; <source>American Journal of Preventive Medicine</source><volume>54</volume>, no. <issue>5</issue>: <fpage>652</fpage>&#8211;<lpage>660</lpage>. <pub-id pub-id-type="doi">10.1016/j.amepre.2018.01.034</pub-id>.<pub-id pub-id-type="pmid">29551331</pub-id></mixed-citation></ref><ref id="msc70084-bib-0040"><mixed-citation publication-type="journal" id="msc70084-cit-0040"><string-name name-style="western"><surname>Qaseem</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>T. J.</given-names><surname>Wilt</surname></string-name>, <string-name name-style="western"><given-names>R. M.</given-names><surname>McLean</surname></string-name>, and <string-name name-style="western"><given-names>M. A.</given-names><surname>Forciea</surname></string-name>. , and <collab collab-type="authors">Clinical Guidelines Committee of the American College of, P</collab>
. <year>2017</year>. &#8220;<article-title>Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians</article-title>.&#8221; <source>Annals of Internal Medicine</source><volume>166</volume>, no. <issue>7</issue>: <fpage>514</fpage>&#8211;<lpage>530</lpage>. <pub-id pub-id-type="doi">10.7326/M16-2367</pub-id>.<pub-id pub-id-type="pmid">28192789</pub-id></mixed-citation></ref><ref id="msc70084-bib-0041"><mixed-citation publication-type="book" id="msc70084-cit-0041"><collab collab-type="authors">RAMQ</collab>
. (<year>2011</year>). &lt;&#8220;<part-title>R&#233;gie de l&#8217;assurance maladie du Qu&#233;bec</part-title> &#8221;.<source>List of Medications</source> . Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.prod.ramq.gouv.qc.ca/DPI/PO/Commun/PDF/Liste_Med/Liste_Med/liste_med_cor1_2010_06_01_en.pdf" ext-link-type="uri">https://www.prod.ramq.gouv.qc.ca/DPI/PO/Commun/PDF/Liste_Med/Liste_Med/liste_med_cor1_2010_06_01_en.pdf</ext-link> . Accessed December 27, 2011.&gt;.</mixed-citation></ref><ref id="msc70084-bib-0042"><mixed-citation publication-type="journal" id="msc70084-cit-0042"><string-name name-style="western"><surname>Robertson</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><given-names>L. A. G.</given-names><surname>Marshman</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Plummer</surname></string-name>, and <string-name name-style="western"><given-names>E.</given-names><surname>Downs</surname></string-name>. <year>2019</year>. &#8220;<article-title>Effect of Gabapentin vs Pregabalin on Pain Intensity in Adults With Chronic Sciatica: A Randomized Clinical Trial</article-title>.&#8221; <source>JAMA Neurology</source><volume>76</volume>, no. <issue>1</issue>: <fpage>28</fpage>&#8211;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1001/jamaneurol.2018.3077</pub-id>.<pub-id pub-id-type="pmid">30326006</pub-id><pub-id pub-id-type="pmcid">PMC6439871</pub-id></mixed-citation></ref><ref id="msc70084-bib-0043"><mixed-citation publication-type="journal" id="msc70084-cit-0043"><string-name name-style="western"><surname>Shanthanna</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Gilron</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Rajarathinam</surname></string-name>, et&#160;al. <year>2017</year>. &#8220;<article-title>Benefits and Safety of Gabapentinoids in Chronic Low Back Pain: A Systematic Review and Meta&#8208;Analysis of Randomized Controlled Trials</article-title>.&#8221; <source>PLoS Medicine</source><volume>14</volume>, no. <issue>8</issue>: <elocation-id>e1002369</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pmed.1002369</pub-id>.<pub-id pub-id-type="pmid">28809936</pub-id><pub-id pub-id-type="pmcid">PMC5557428</pub-id></mixed-citation></ref><ref id="msc70084-bib-0044"><mixed-citation publication-type="journal" id="msc70084-cit-0044"><string-name name-style="western"><surname>Skolnick</surname>, <given-names>P.</given-names></string-name><year>2018</year>. &#8220;<article-title>The Opioid Epidemic: Crisis and Solutions</article-title>.&#8221; <source>Annual Review of Pharmacology and Toxicology</source><volume>58</volume>, no. <issue>1</issue>: <fpage>143</fpage>&#8211;<lpage>159</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-pharmtox-010617-052534</pub-id>.<pub-id pub-id-type="pmid">28968188</pub-id></mixed-citation></ref><ref id="msc70084-bib-0045"><mixed-citation publication-type="journal" id="msc70084-cit-0045"><string-name name-style="western"><surname>Soni</surname>, <given-names>A.</given-names></string-name>, and <string-name name-style="western"><given-names>P.</given-names><surname>Walters</surname></string-name>. <year>2019</year>. &#8220;<article-title>A Study of the Reasons for Prescribing and Misuse of Gabapentinoids in Prison Including Their Co&#8208;prescription With Opioids and Antidepressants</article-title>.&#8221; <source>International Journal of Prisoner Health</source><volume>16</volume>, no. <issue>1</issue>: <fpage>67</fpage>&#8211;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1108/ijph-01-2019-0004</pub-id>.<pub-id pub-id-type="pmid">32040271</pub-id></mixed-citation></ref><ref id="msc70084-bib-0046"><mixed-citation publication-type="journal" id="msc70084-cit-0046"><string-name name-style="western"><surname>Soprano</surname>, <given-names>S. E.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Hennessy</surname></string-name>, <string-name name-style="western"><given-names>W. B.</given-names><surname>Bilker</surname></string-name>, and <string-name name-style="western"><given-names>C. E.</given-names><surname>Leonard</surname></string-name>. <year>2020</year>. &#8220;<article-title>Assessment of Physician Prescribing of Muscle Relaxants in the United States, 2005&#8211;2016</article-title>.&#8221; <source>JAMA Network Open</source><volume>3</volume>, no. <issue>6</issue>: <elocation-id>e207664</elocation-id>. <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.7664</pub-id>.<pub-id pub-id-type="pmid">32579193</pub-id><pub-id pub-id-type="pmcid">PMC7315288</pub-id></mixed-citation></ref><ref id="msc70084-bib-0047"><mixed-citation publication-type="journal" id="msc70084-cit-0047"><string-name name-style="western"><surname>Stokes</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>K. M.</given-names><surname>Berry</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Hempstead</surname></string-name>, <string-name name-style="western"><given-names>D. J.</given-names><surname>Lundberg</surname></string-name>, and <string-name name-style="western"><given-names>T.</given-names><surname>Neogi</surname></string-name>. <year>2019</year>. &#8220;<article-title>Trends in Prescription Analgesic Use Among Adults With Musculoskeletal Conditions in the United States, 1999&#8208;2016</article-title>.&#8221; <source>JAMA Network Open</source><volume>2</volume>, no. <issue>12</issue>: <elocation-id>e1917228</elocation-id>. <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2019.17228</pub-id>.<pub-id pub-id-type="pmid">31825504</pub-id><pub-id pub-id-type="pmcid">PMC6991204</pub-id></mixed-citation></ref><ref id="msc70084-bib-0048"><mixed-citation publication-type="journal" id="msc70084-cit-0048"><string-name name-style="western"><surname>Tharp</surname>, <given-names>A. M.</given-names></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Hobron</surname></string-name>, and <string-name name-style="western"><given-names>T.</given-names><surname>Wright</surname></string-name>. <year>2019</year>. &#8220;<article-title>Gabapentin&#8208;related Deaths: Patterns of Abuse and Postmortem Levels</article-title>.&#8221; <source>Journal of Forensic Sciences</source><volume>64</volume>, no. <issue>4</issue>: <fpage>1105</fpage>&#8211;<lpage>1111</lpage>. <pub-id pub-id-type="doi">10.1111/1556-4029.14021</pub-id>.<pub-id pub-id-type="pmid">30731020</pub-id></mixed-citation></ref><ref id="msc70084-bib-0049"><mixed-citation publication-type="journal" id="msc70084-cit-0049"><string-name name-style="western"><surname>Trudel</surname>, <given-names>X.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Gilbert&#8208;Ouimet</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Milot</surname></string-name>, et&#160;al. <year>2018</year>. &#8220;<article-title>Cohort Profile: The PROspective Qu&#233;bec (PROQ) Study on Work and Health</article-title>.&#8221; <source>International Journal of Epidemiology</source><volume>47</volume>, no. <issue>3</issue>: <fpage>693</fpage>&#8211;<lpage>693i</lpage>. <pub-id pub-id-type="doi">10.1093/ije/dyy026</pub-id>.<pub-id pub-id-type="pmid">29534180</pub-id><pub-id pub-id-type="pmcid">PMC6005032</pub-id></mixed-citation></ref><ref id="msc70084-bib-0050"><mixed-citation publication-type="journal" id="msc70084-cit-0050"><string-name name-style="western"><surname>Turner</surname>, <given-names>J. A.</given-names></string-name>, and <string-name name-style="western"><given-names>M. C.</given-names><surname>Denny</surname></string-name>. <year>1993</year>. &#8220;<article-title>Do Antidepressant Medications Relieve Chronic Low Back Pain?</article-title>&#8221; <source>Journal of Family Practice</source><volume>37</volume>, no. <issue>6</issue>: <fpage>545</fpage>&#8211;<lpage>553</lpage>.<pub-id pub-id-type="pmid">8245805</pub-id></mixed-citation></ref><ref id="msc70084-bib-0051"><mixed-citation publication-type="journal" id="msc70084-cit-0051"><string-name name-style="western"><surname>Vargas&#8208;Schaffer</surname>, <given-names>G.</given-names></string-name><year>2010</year>. &#8220;<article-title>Is the WHO Analgesic Ladder Still Valid? Twenty&#8208;Four Years of Experience</article-title>.&#8221; <source>Canadian Family Physician</source><volume>56</volume>, no. <issue>6</issue>: <fpage>514</fpage>&#8211;<lpage>517e202</lpage>.<pub-id pub-id-type="pmid">20547511</pub-id><pub-id pub-id-type="pmcid">PMC2902929</pub-id></mixed-citation></ref><ref id="msc70084-bib-0052"><mixed-citation publication-type="journal" id="msc70084-cit-0052"><string-name name-style="western"><surname>Viniol</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Ploner</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Hickstein</surname></string-name>, et&#160;al. <year>2019</year>. &#8220;<article-title>Prescribing Practice of Pregabalin/gabapentin in Pain Therapy: An Evaluation of German Claim Data</article-title>.&#8221; <source>BMJ Open</source><volume>9</volume>, no. <issue>3</issue>: <elocation-id>e021535</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmjopen-2018-021535</pub-id>.<pub-id pub-id-type="pmcid">PMC6475154</pub-id><pub-id pub-id-type="pmid">30928920</pub-id></mixed-citation></ref><ref id="msc70084-bib-0053"><mixed-citation publication-type="journal" id="msc70084-cit-0053"><string-name name-style="western"><surname>West</surname>, <given-names>N. A.</given-names></string-name>, <string-name name-style="western"><given-names>S. G.</given-names><surname>Severtson</surname></string-name>, <string-name name-style="western"><given-names>J. L.</given-names><surname>Green</surname></string-name>, and <string-name name-style="western"><given-names>R. C.</given-names><surname>Dart</surname></string-name>. <year>2015</year>. &#8220;<article-title>Trends in Abuse and Misuse of Prescription Opioids Among Older Adults</article-title>.&#8221; <source>Drug and Alcohol Dependence</source><volume>149</volume>: <fpage>117</fpage>&#8211;<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2015.01.027</pub-id>.<pub-id pub-id-type="pmid">25678441</pub-id></mixed-citation></ref><ref id="msc70084-bib-0054"><mixed-citation publication-type="journal" id="msc70084-cit-0054"><string-name name-style="western"><surname>Yu</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Appleyard</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Cottrell</surname></string-name>, and <string-name name-style="western"><given-names>G.</given-names><surname>Peat</surname></string-name>. <year>2021</year>. &#8220;<article-title>Co&#8208;prescription of Gabapentinoids and Opioids Among Adults With and Without Osteoarthritis in the United Kingdom Between 1995 and 2017</article-title>.&#8221; <source>Rheumatology</source><volume>60</volume>, no. <issue>4</issue>: <fpage>1942</fpage>&#8211;<lpage>1950</lpage>. <pub-id pub-id-type="doi">10.1093/rheumatology/keaa586</pub-id>.<pub-id pub-id-type="pmid">33159800</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>